Objective: To determine the efficacy of a long-acting oxyntomodulin (OXM) analogue, OXM6421, in inhibiting food intake and decreasing body weight in lean and diet-induced obese (DIO) rodents. Research design and methods: The glucagon-like peptide-1 (GLP-1) receptor binding affinity and efficacy, sensitivity to enzymatic degradation in vitro and persistence in the circulation after peripheral administration were investigated for OXM6421 and compared with native OXM. The chronic effect of OXM6421 on food intake, body weight and energy expenditure was examined in lean rats, and its anti-obesity potential was evaluated in DIO mice. Results: OXM6421 showed enhanced GLP-1 receptor binding affinity and cyclic adenosine monophosphate (cAMP) stimulation, and higher resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP) compared with native OXM. OXM6421 persisted longer in the circulation than OXM after peripheral administration. Acute administration of OXM6421 potently inhibited food intake in lean rodents, with cumulative effects lasting up to 24 h. In lean rats, daily subcutaneous (s.c.) administration of OXM6421 caused greater weight loss than the pair-fed animals, and a higher rate of oxygen consumption than both the pair-fed and the saline controls. In DIO mice, continuous s.c. infusion of OXM6421 resulted in a significant weight loss, accompanied by an improvement in glucose homeostasis and an increase in circulating adiponectin levels. Once-daily s.c. administration of OXM6421 for 21 days caused sustained weight loss in DIO mice. Conclusion: OXM6421 induces negative energy balance in both lean and obese rodents, suggesting that long-acting OXM analogues may represent a potential therapy for obesity.
Introduction
Obesity is a global health problem, with its prevalence increasing at an alarming rate. 1, 2 It is associated with an increased premature mortality because of many serious conditions, including type II diabetes, cardiovascular disease and various types of cancer. 3, 4 Thus, medical treatment of obesity has become a necessity. However, the currently available anti-obesity drugs are only moderately effective and all have associated side effects. 5 At present, the most effective treatment for obesity is bariatric surgery, 6 but its cost and associated mortality make it impractical to cope with the obesity epidemic. 7 Thus, there is a vast unmet medical demand for a safe and effective anti-obesity therapy. Recent evidence suggests that neural and endocrine signalling from the gut has an important physiological role in postprandial satiety and manipulation of the gut-brain axis may offer targets for future obesity therapies. 8 Oxyntomodulin (OXM), a 37-amino-acid peptide, is a product of the proglucagon gene that is released postprandially from the L-cells of the small intestine in proportion to calorie intake. 9 The appetite-suppressing and weight-reducing effects of OXM have been shown in both rodents and humans. [10] [11] [12] OXM is thus a putative target for obesity therapy. However, its clinical utility is limited, mainly because of its short circulating half-life, which is estimated to be approximately 12 min. 13 This is a major drawback, as multiple daily doses of large quantities of peptide would be required to sustain its effect, making it medically and economically unviable as an anti-obesity agent. It has been shown that renal clearance accounts for 35% of the peptide disappearance from the plasma after OXM administration in rats. 14 In vitro protease degradation assays suggest that OXM may be susceptible to proteolysis by dipeptidyl peptidase IV (DPP-IV) 15 and neutral endopeptidase 24.11 (NEP). 16, 17 To overcome the factors limiting OXM as a potential anti-obesity therapy, we have recently investigated the structure-function relationships and the degradation pathways of OXM, and identified the parts of the OXM sequence that are sensitive to degradation and/or involved in the binding to the glucagon-like peptide-1 (GLP-1) receptor. 18 Several novel peptide analogues of OXM were synthesized, incorporating changes to the amino-acid sequence that were intended primarily to confer resistance against degradation by proteases (DPP-IV and NEP), and enhance binding affinity for the GLP-1 receptor. One OXM analogue, coded OXM6421, showed the greatest potential in initial feeding studies in lean rodents.
In this study, we characterized the long-acting OXM analogue OXM6421, investigating its binding affinity to the GLP-1 receptor and stimulation of cyclic adenosine monophosphate (cAMP) production, its effects on the release of hypothalamic neuropeptides and its sensitivity in vitro to degradation by DPP-IV and NEP. The rate of peptide disappearance from plasma following peripheral administration was also examined and compared with OXM. The chronic effects of OXM6421 on food intake, body weight and energy expenditure were investigated in lean rats. Its anti-obesity potential was evaluated in diet-induced obese (DIO) mice. The results suggest that OXM6421 may offer greater potential as an obesity therapy than native OXM.
Materials and methods

Materials
OXM analogue OXM6421 was synthesized by BioMol International LP (Exeter, UK). Human/mouse/rat OXM (all have the same sequence) was obtained from Bachem (St Helens, UK) and was used for all studies described below.
Animals
One hundred and fifty-five male Wistar rats (250-300 g; Charles River, UK) and fifty-four C57BL/6 male mice (20-25 g, Harlan, UK) were singly housed and maintained at 21-23 1C under a 12:12 h light-dark cycle (light period 0700-1900 h) with free access to normal chow (RMI diet, Special Diet Services, Witham, UK) and water. For the DIO model, 60, 6-week-old C57BL/6 male mice (Harlan, UK) were maintained on a high-fat diet (60% fat kcal; D12492, Research Diets, New Brunswick, NJ, USA) for 18 weeks. 19 All animal procedures undertaken were approved by the British Home Office Animals (Scientific Procedures) Act 1986 (Project License 70/6402).
GLP-1 receptor binding assay
Rat lung has been shown to have high levels of GLP-1 receptor and studies have shown that the binding values using rat lung membrane are comparable to those from GLP-1 receptor over-expressing cell lines. 20 Plasma membranes from rat lung tissue were prepared and used as previously described. 21 Exendin-4 was used as label due to the instability of GLP- 
Hypothalamic explant static incubation system
The effect of OXM6421 on the hypothalamic release of neuropeptides was determined as previously described. 22 Briefly, hypothalamic explants from male Wistar rats were incubated with OXM6421 at 10, 100 and 1000 nM for 45 min in 600 ml of artificial cerebrospinal fluid after an initial 2-h equilibration and a 45-min basal incubation period. The viability of the tissue was verified by a final 45-min exposure to artificial cerebrospinal fluid containing 56 mM KCl. At the end of each period, the artificial cerebrospinal fluid was
Oxyntomodulin analogue reduces body weight Y-L Liu et al collected and stored at À20 1C until the measurement of hypothalamic hormones. Levels of alpha-melanocytestimulating hormone (a-MSH), cocaine-and amphetaminerelated transcript (CART), Agouti-related protein (Agrp) and neuropeptide Y (NPY) were measured using our in-house radioimmunoassays as previously described. [23] [24] [25] In vitro degradation assays DPP-IV protease assay. Digest buffer (100 mM TRIS-HCl, pH 8) containing 15 mM of peptide and 1 mg of porcine kidney DPP-IV (Sigma, Missouri, USA) was incubated at 37 1C. The reaction was terminated at the specified timepoint by addition of 5 ml 10% trifluoroacetic acid. The incubated samples were analysed by reverse-phase highpressure liquid chromatography (Jasco HPLC system, Jasco Ltd., Great Dunmow, UK; Phenomenex, Phenomenex Ltd., Macclesfield, UK) Gemini C18 250 mm Â 4.6 mm column, linear gradient of 27-31% acetronitrile in 0.05% trifluoroacetic acid/water in 0.05% trifluoroacetic acid over 50 min at 1 ml min
À1
. Peptides and their degradation products were monitored by their absorbance at 214 nm. Percentage degradation was quantified by integration of peak areas related to undigested peptide peaks. 18 NEP protease assay. The NEP protease assay was completed as in the DPP-IV assay, except for the following changes: digest buffer (50 mM TRIS-HCl, 50 mM NaCl pH 7.5) and 200 ng of recombinant human NEP-2 (R&D Systems, Wiesbaden, Germany). The incubated samples were run and analysed as above, but with a linear gradient of acetonitrile in 0.05% trifluoroacetic acid (15-60% acetonitrile over 30 min). Degradation products were monitored by their absorbance at 214 nm. 18 In vivo disappearance times of OXM6421 compared with OXM To investigate the longevity of detectable levels of OXM6421 and OXM in the circulation, rats were anaesthetized with an intraperitoneal administration of a mixture of hypnorm (fentanyl citrate and fluanisone, VetaPharma, Leeds, UK) and hypnovel (midazolam hydrochloride, Roche, Herts, UK). The jugular vein was cannulated and blood samples were drawn immediately before (baseline), and at 5, 10, 20, 30, 60, 90 and 120 min after a subcutaneous (s.c.) administration of either 20 nmol kg À1 OXM6421 or 2000 nmol kg À1 OXM (these doses were approximately equivalent in their anorectic effect during the first 2 h after peptide administration in early doseranging studies). Plasma levels of OXM-like activity were measured using established in-house radioimmunoassays. 9 For the OXM6421 assay, the antisera (raised in a rabbit immunized with OXM6421 conjugated to bovine serum albumin by carbodiimide) cross-react 100% with OXM6421, o0.05% with OXM and extendin-4, and o0.01% with GLP-1 and glucagon. The 125 I-OXM6421 label was prepared using the iodogen method and purified by high-pressure liquid chromatography. The specific activity of OXM6421 label was 53 Bq fmol
. Acute feeding study in fasted lean rats Rats were fasted for 24 h and received a s.c. administration of either OXM6421 (10 nmol kg À1 ) or saline (maximum volume of 0.15 ml) between 0900 and 1000 hours. A pre-weighed amount of normal chow was provided to the rats immediately after the injection and food consumption was measured at 1, 2, 4, 6, 8 and 24 h after injection.
Effects of daily peripheral injection of OXM6421 on food intake and body weight in lean rats As 10 nmol kg À1 OXM6421 inhibited food intake significantly, 5 and 20 nmol kg À1 doses of OXM6421 were chosen for the daily administration study. To test the effectiveness of these doses on acute feeding, rats were fasted overnight before receiving their first s.c. administration of 5 or 20 nmol kg À1 of either OXM6421 or saline. Based on the pharmacokinetic characteristics of OXM6421, a washout period was not considered necessary before proceeding with the daily administration study. The animals continued to receive a daily s.c. administration of either saline or OXM6421 (5 or 20 nmol kg
) at between 0900 and 1000 hours for a further 13 days, with both food and body weight measured daily. Treatment was withdrawn on day 14 (first dose was given on day 0) and daily food intake and body weight measurements continued for a further 14 days (follow-up period).
Effects of continuous s.c. infusion of OXM6421 on energy expenditure in lean rats
To investigate the effect of OXM6421 on energy expenditure, a pair-feeding paradigm was first used to examine whether the reduction in weight gain in the OXM6421-treated rats was attributable solely to the reduction of food intake. This was followed by the measurement of oxygen consumption by indirect calorimetry with the Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments, Columbus, OH, USA), with the goal of assessing resting energy expenditure.
Rats were acclimatized to the Comprehensive Laboratory Animal Monitoring System for 48 h before pump implantation. They were then randomized into three groups of approximately equal body weight (control, pair-fed and OXM6421). On the morning of the surgery, Alzet osmotic pumps (Durect; Model 2001; duration: 7 days) were implanted in the interscapular region under isoflurane anaesthesia. The mini-pumps for both control and pair-fed groups contained saline, whereas the OXM6421 group contained OXM6421 at an infusion rate of 30 pmol kg À1 min
À1
. This dose was selected on the basis of initial dose-ranging feeding studies with OXM and OXM analogues, in which we had found that a total daily infusion dose of approximately two-fold the acutely effective dose (i.e. 20 nmol kg À1 s.c.) is required to effectively reduce food intake and body weight. After the surgery, rats were allowed to recover, returned to their home cage and their food and body weight measured daily at 0900-1000 hours.
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Animals in the control and OXM6421 groups had ad libitum access to food. The pair-fed animals (pumps contained no OXM6421) were food restricted to receive the median daily food intake of the OXM6421-treated group from the previous day. On day 8, animals were transferred to the Comprehensive Laboratory Animal Monitoring System without food for a period of 6 h (0900-1500 hours). Oxygen consumption (ml kg 0.75 h
À1
) was measured by indirect calorimetry at 24 1C. Locomotor activity was measured simultaneously using optical beam sensors (Opto M3 animal activity meter; Columbus Instruments, Columbus, OH, USA).
Acute feeding study in lean mice
To test the effectiveness of OXM6421 in a second species, an acute feeding study was carried out in over-night fasted C57BL/6 mice and compared with OXM. Mice received an intraperitoneal. administration (injection was with a 28-gauge needle and a maximum volume 120 ml) of either OXM6421 (5 or 20 nmol kg À1 ), or OXM (20 or 2000 nmol kg
À1
) or saline at between 0900 and 1000 hours. Following injection, animals were returned to their home cages containing a pre-weighed amount of food, which was re-weighed at 1, 2, 4, 6 and 24 h post injection.
Effects of continuous s.c. infusion of OXM6421 or OXM on food intake and body weight in DIO mice
Male DIO mice were randomized by body weight into four groups, and were implanted with Alzet osmotic pumps (Durect; Model 1007D, DURECT Corporation, Cupertino, CA, USA) containing either OXM6421 at a delivery rate of 10 or 30 pmol kg min Fapproximately twofold of the acute effective dose for the inhibition of food intake), or saline. 18 Food intake and body weight were monitored daily between 0900 and 1000 hours for 7 days. On day 8, mice were killed and blood collected by cardiac puncture. Blood glucose concentration was measured immediately with an Ascensia contour blood glucose meter (Bayer Healthcare, Newbury, UK). Plasma was stored at À20 1C for the determination of insulin, leptin and adiponectin levels by radioimmunoassays (Linco Research, Billerica, MA, USA). The residual pump contents were extracted and stored at -20 1C for analysis by high-pressure liquid chromatography.
Effects of daily peripheral injection of OXM6421 on food intake and body weight in DIO mice To test the sensitivity of the DIO mice to an acute s.c. dose of OXM6421, they were fasted overnight before receiving their first injection on day 0, and food intake (high-fat chow) measured at 1, 2, 4, 6 and 24 h. Thereafter, DIO mice were daily subcutaneously administered either saline or OXM6421 (20 nmol kg À1 ) for 21 days (starting from day 0) at 0900-1000 hours. The mice were maintained on the highfat diet for the duration of the study with food intake and body weight monitored daily. Treatments were withdrawn on day 21. Daily food intake and body weight measurements were continued for a further 14 days.
Statistical analysis
Statistical advice was obtained from the Imperial College Statistical Advisory Service (Imperial College London). Results are shown as mean and s.e.m. Ex vivo data from hypothalamic static incubation experiments were analysed using a paired t-test to compare the basal and test periods for each explant. An unpaired t-test was used for the in vitro data and the disappearance times from plasma. Multiple data from acute feeding studies and plasma measurements were analysed using one-way statistical analysis of variance followed by post-hoc Dunnet's test. In all cases, a Po0.05 was considered to be statistically significant. Chronic studies were analysed using a non-parametric two-sample Wilcoxon rank-sum (Mann-Whitney) test comparing the treatment group with the control group. Generalized estimating equation was used to compare the control and treatment groups over the entire study period. Statistical analysis was performed using Stata 9 (StataCorp, College Station, TX, USA).
Results
Comparison of GLP-1 receptor binding affinity and cAMP production of OXM6421 with OXM OXM6421 showed a 30-fold greater affinity for the GLP-1 receptor than OXM as shown by the IC 50 values (0.98 versus 29.1 nM; Po0.001; n ¼ 3-4; Table 1 ). The affinity of OXM for the GLP-1 receptor was similar to that found in our earlier studies comparing the IC 50 of OXM, GLP-1, and exendin-4 (33.1, 0.34, and 0.27 nM, respectively). 18 In accord with these results, OXM6421 was 30-fold more potent at stimulating cAMP levels in Chinese hamster lung fibroblast cells stably transfected with rat GLP-1 receptor (Po0.001; n ¼ 3-4; Table 1 ).
Effect of OXM6421 on ex vivo release of neuropeptides from rat hypothalamus OXM6421 at 100 and 1000 nM significantly increased alpha-melanocyte-stimulating hormone release from hypothalamic explants (161 and 177% versus their baseline Table 1 GLP-1 receptor binding activity, cAMP production and sensitivity to protease degradation of OXM6421 and oxyntomodulin (OXM)
OXM OXM6421
GLP-1 receptor affinity IC 50 (nM) 2 9 . 1 ± 4.4 0.98 ± 0.11*** cAMP production EC 50 (nM) 0.65 ± 0.08 0.021 ± 0.005*** DPP-IV degradation at 2 h (%) 100 ± 0 0 Neprilysin degradation at 2 h (%) 77 ± 5 4 ± 2*** Abbreviations: cAMP, cyclic adenosine monophosphate; DPP-IV, dipeptidyl peptidase IV; GLP-1, glucagon-like peptide-1; OXM, oxyntomodulin. Results are means ± s.e.m.; n ¼ 3-4. ***Po0.001 versus OXM.
Oxyntomodulin analogue reduces body weight Y-L Liu et al values, respectively; Po0.05; n ¼ 7-9). However, OXM6421 had no significant effect on cocaine-and amphetamineregulated transcript, Agouti-related protein and neuropeptide-Y release (Figure 1 ).
In vitro degradation of OXM6421 compared with OXM When peptides were incubated with DPP-IV (1 mg) for a period of 2 h, no degradation of OXM6421was observed, whereas no OXM was detectable after 2 h incubation. Degradation of OXM6421 by NEP (200 ng) was also markedly reduced compared with OXM (4 and 77% degradation for OXM6421 and OXM, respectively; n ¼ 3; Table 1 ).
In vivo disappearance time of OXM6421 versus OXM in lean rats Both OXM6421 and OXM reached peak plasma concentration by approximately 10 min post s.c. administration (n ¼ 5). However, plasma levels of OXM declined sharply by 30 min post administration, whereas plasma levels of OXM6421 remained elevated throughout the whole study duration (2 h; Figure 2 ).
Effects of a single dose of OXM6421 on food intake in fasted lean rats OXM6421 (10 nmol kg
À1
) caused a significant, 54% reduction in cumulative food intake over 8 h (Po0.0001) compared with the saline controls. At 24 h post injection, cumulative food intake of the OXM6421 group was 13% less than that of the saline controls (Po0.001; n ¼ 10; Figure 3 ). However, there were signs of the anorectic effect waning between 8 and 24 h.
Effects of chronic daily administration of OXM6421 on food intake and body weight gain in lean rats Based on the results of the acute feeding study in rats, two doses (5 and 20 nmol kg À1 ) were chosen for the chronic study assessing the effects of OXM6421 in reducing food intake and body weight gain in rats. The 5 nmol kg À1 daily dose of OXM6421 had no significant effect on cumulative food Oxyntomodulin analogue reduces body weight Y-L Liu et al intake or body weight change. However, at 20 nmol kg À1 , OXM6421 caused a 15% reduction in total food intake over the 14-day treatment period (Po0.01 versus saline; n ¼ 8-9; Figures 4a and b) . Daily food intake during the post-treatment period was similar between the groups (Figure 4b) .
From day 4, body weight was significantly lower in the OXM6421 20 nmol kg À1 group (Po0.05). At the end of the 14-day treatment period, body weight in the OXM6421-treated rats was 9% less than that of the controls (Po0.01). The significant weight reduction was sustained for the period studied after withdrawal of the treatment (Figure 4c ).
Energy expenditure following continuous s.c. infusion of OXM6421, compared with pair-fed and control lean rats Cumulative food intake over the 7-day period was reduced by 36% in the OXM6421-treated (30 pmol kg min
) compared with the saline controls (Po0.001; Figure 5a ). Body weight was decreased in both OXM6421 and pair-fed groups (Po0.001 versus saline control), and the weight loss in the OXM6421 group was significantly greater than that in the pair-fed group (Po0.05 versus pair-fed; n ¼ 12; Figure 5b ). During subsequent monitoring in the Comprehensive Laboratory Animal Monitoring System, there was a significant difference in oxygen consumption between the control and the OXM6421-treated (Po0.0001; generalized estimating equation), and between the pair-fed and the OXM6421-treated (Po0.0001; generalized estimating equation), but not between the control and the pair-fed animals (Figure 5c ). OXM6421 increased the mean oxygen consumption compared with both the control and the pair-fed groups (ml kg 0.75 h
: 2403 ± 84 for the control; 2812 ± 48 for the OXM6421-treated; 2530 ± 45 for the pair-fed; Po0.01; Figure 5d ). The mean body weights on the morning of the VO 2 measurement were: 345, 303 and 311 g for the control, OXM6421 and the pair-fed groups, respectively. Locomotor activity was not affected by OXM6421 treatment (Figure 5e ). ) reduced food intake in the first hour compared with the saline control (Po0.01 versus saline; n ¼ 10-12; Figure 6 ), but the effect was lost by 2 h with OXM. In contrast, both doses of OXM6421 significantly reduced 24 h food intake compared with the saline controls (Po0.01; Figure 6 ). , OXM6421 caused a significant, 34% reduction in the cumulative food intake (Po0.001 versus saline controls; n ¼ 9-10; Figure 7a ). Weight loss from their initial body weight after 7 days was 9.0 ± 1.1% in the OXM6421 30 pmol kg À1 min À1 group compared with Oxyntomodulin analogue reduces body weight Y-L Liu et al 1.6 ± 0.8% in the control group (Po0.01; Figure 7b ). Highpressure liquid chromatography analysis of post-study pump contents revealed that there was no significant peptide degradation in any of the treatment groups (data not shown). In addition, 7-day infusion of OXM6421 at 30 pmol kg À1 min À1 resulted in a significant decrease in (n ¼ 7-10). *Po0.05; **Po0.01; ***Po0.001 compared to saline. Figure 8a ). Mice receiving OXM6421 lost weight during the treatment period, whereas the control group gained weight. At the end of the 21-day treatment, body weight in the OXM6421-treated mice was 11% lower than that of the saline controls (Po0.01; Figure 8b ). Withdrawal of the treatment resulted in weight gain in both groups; despite this, the difference between the two groups in cumulative body weight change remained significant over the entire study period (Figure 8b ). All animals appeared healthy with no obvious behavioural abnormalities.
Discussion
Our results showed for the first time that a long-acting OXM analogue, termed OXM6421, effectively reduced body weight in two rodent species. In the DIO mice (a model that shares a number of traits with human obesity), oncedaily s.c. administration of OXM6421 for 21 days produced approximately 11% weight loss compared with the saline controls, indicating its potential as an anti-obesity therapy.
Although earlier studies have shown the potential of OXM to reduce body weight, [10] [11] [12] its clinical usage as an obesity therapy is limited because of its rapid clearance and short circulating half-life. Both DPP-IV and NEP have been shown to degrade OXM in vitro. [15] [16] [17] Evidence of the involvement of DPP-IV in the breakdown of OXM in vivo came from our recent study that co-administration of OXM and a DPP-IV inhibitor resulted in a greater reduction of food intake. 18 The resistance of OXM6421 to degradation by the enzymes DPP-IV and NEP observed in the present study is likely responsible for its prolonged anorectic effect. The longer circulating time compared with native OXM following peripheral administration indicates that OXM6421 has an improved pharmacokinetics, which is consistent with its long-lasting inhibition of food intake. It has been suggested that the anorectic effect of OXM may be mediated by the GLP-1 receptor, as the effects were blocked by the GLP-1 receptor antagonist exendin and were absent in the GLP-1 receptor knockout mouse. 26 The marked enhancement of GLP-1 binding and cAMP production with OXM6421 may account for its increased potency in the acute feeding study in mice.
In lean Wistar rats, chronic treatment with a relatively small daily dose of OXM6421 (20 nmol kg À1 ) significantly decreased cumulative food intake, and caused a 9% reduction in weight gain after 14-day treatment compared with the controls. The results of the pair-feeding study suggested that OXM6421 induced negative energy balance by affecting both energy intake and expenditure. The OXM6421-treated rats lost significantly more weight than that of the pair-fed group, indicating that inhibition of food intake was not solely responsible for the weight loss. The effect on energy expenditure was then confirmed by studies in the Comprehensive Laboratory Animal Monitoring System. Resting energy expenditure (measured as oxygen consumption in *** Oxyntomodulin analogue reduces body weight Y-L Liu et al the light-phase) was significantly higher in the OXM6421-treated than both the pair-fed and the control rats. Interestingly, it has been shown that OXM did not affect basal resting energy expenditure in humans, and the observed increase in total energy expenditure was because of an increase in activity during the 'free-living' period. 27 Further studies are required to clarify whether these discrepancies reflect differences between species or pathways activated. The precise mechanism whereby OXM6421 induces negative energy balance is not known at present. The central satiety action of native OXM is thought to mediate through the hypothalamus and brainstem. An increase in alphamelanocyte-stimulating hormone has been reported earlier with OXM. 10 In the present study, OXM6421 was also found to increase alpha-melanocyte-stimulating hormone release from rat hypothalamus, without significant effects on neuropeptide-Y, Agouti-related protein and cocaine-and amphetamine-regulated transcript release. It is well established that the melanocortin system has an important role in the regulation of energy homeostasis. 28 In addition to its anorectic action, alpha-melanocyte-stimulating hormone has been shown to activate the brown adipose tissue through its sympathetic innervations 29 and increase resting energy expenditure. 30 Thus, it is possible that OXM6421 may induce negative energy balance, at least in part, through the melanocortin system. Further studies are required before a definitive conclusion can be made with regard to the mechanism of action of OXM6421. Interestingly, it has recently been shown that GLP-1 and glucagon receptors' dual agonism can reverse obesity in rodents, 31, 32 which further highlights the important role of the peptides from the pre-proglucagon family in the modulation of energy balance.
The anti-obesity potential of OXM6421 was determined in DIO mice, a well-characterized rodent model that shows many of the metabolic consequences of human obesity (including insulin resistance, glucose intolerance, leptin resistance and increased expression of inflammatory markers). 33 Continuous infusion of OXM6421 dose-dependently reduced cumulative food intake and, at 30 pmol kg À1 min
À1
, caused a significant weight loss over a 7-day infusion period. This weight loss was accompanied by a significant increase in plasma adiponectin levels and a reduction in plasma leptin levels (although this did not reach statistical significance), suggesting that the weight loss was at least partly due to the reduction in adipose tissue. Moreover, blood glucose level was also significantly reduced, together with a 31% reduction in plasma insulin level, indicating that there may be an improvement in insulin sensitivity, probably as a result of the weight loss. Whether OXM6421 has any direct effect on glucose homeostasis remains to be investigated. However, a recent study has shown that OXM did not affect insulin action on glucose disposal and production during a hyperinsulinemic euglycaemic clamp study in DIO mice. 34 Furthermore, in DIO mice, the weight loss after 21 days daily s.c. administration was of similar magnitude to that observed in the lean rats, and there was no evidence of decreasing sensitivity to OXM6421 over time. Tachyphylaxis may be less of a problem with gut hormone-based therapy than with other weight-reducing agents, because they are released daily throughout life, and are chronically elevated in certain endocrine tumours and in gut diseases associated with thinness, as well as after bariatric bypass surgeryF where there is no evidence of escape. However, results from the current study do not provide further information regarding the endogenous functions of OXM, which have been well-documented elsewhere. 8 Although there is no evidence to date suggesting that obese subjects may have a lower level of circulating OXM, elevated OXM levels have been found in patients who have had jejunoileal bypass surgery, 35, 36 which is believed to be at least partly responsible for the successful weight reduction in these patients. In summary, these studies show that OXM6421, an OXM analogue, shows favourable pharmacological characteristics. Its enhanced potency and longevity in suppressing food intake, and the consistent efficacy in reducing body weight at relatively low doses in both lean and obese rodent models suggests that it may have the potential to be an anti-obesity therapy. However, whether those findings in rodents predict an anti-obesity effect in humans remains to be investigated.
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